Vanda Announces Listing of a New HETLIOZ® Patent in the FDA Orange Book

Jul 02, 2015, 09:00 ET from Vanda Pharmaceuticals Inc.

WASHINGTON, July 2, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a HETLIOZ® patent, number 9,060,995 ('995 patent), is now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book.  The '995 patent was issued by the United States Patent and Trademark Office on June 23rd, 2015 and expires in January 2033.  Prior to this newly listed '995 patent, the HETLIOZ® Orange Book listed patents were the U.S. composition of matter '529 patent and the '492 patent, expected to expire in December 2022 (assuming receipt of the five year patent term extension under the Hatch-Waxman Act) and January 2033, respectively.

About Vanda Pharmaceuticals Inc.  Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. For more on Vanda, please visit


Various statements in this release are "forward-looking statements" under the securities laws. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, Vanda's assumptions regarding the life of the HETLIOZ® patents and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2014 and quarterly report on Form 10-Q for the quarter ended March 31, 2015, which are on file with the SEC and available on the SEC's website at In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

Corporate Contact: Jim Kelly Senior Vice President and Chief Financial Officer  Vanda Pharmaceuticals Inc.   (202) 734-3428 

Media Contact: Laney Landsman  Vice President  Makovsky  (212) 508-9643

SOURCE Vanda Pharmaceuticals Inc.